A heparin-like anticoagulant as part of global abnormalities of plasma glycosaminoglycans in a patient with transitional cell carcinoma.

A patient is described in whom a circulating heparin-like anticoagulant developed during the terminal course of metastatic transitional cell carcinoma. The anticoagulant, which was identified as heparan sulfate, was the clinical sign of global abnormalities in the patient's plasma glycosaminoglycans. Subsequent analysis disclosed increased amounts of chondroitin sulfate as well as heparan sulfate. In addition, the charge density and molecular weight of the patient glycosaminoglycans and their organization into proteoglycans differed significantly from glycosaminoglycans isolated from normal plasma samples.

[1]  M. Horne,et al.  Heparin‐like anticoagulant associated with systemic candidiasis , 1990, American journal of hematology.

[2]  M. Horne,et al.  The effect of molecular weight on heparin binding to platelets , 1990, British journal of haematology.

[3]  A. Tefferi,et al.  Circulating heparin-like anticoagulants: report of five consecutive cases and a review. , 1990, The American journal of medicine.

[4]  A. Tefferi,et al.  Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma. , 1989, Blood.

[5]  C. Greenberg,et al.  Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature. , 1989, The American journal of medicine.

[6]  T. Kawai,et al.  Glycosaminoglycans in lung carcinoma. , 1988, Human pathology.

[7]  C. Katlama,et al.  Heparin-like anticoagulant associated with AIDS. , 1987, Thrombosis and haemostasis.

[8]  E. Thonar,et al.  Quantification of keratan sulfate in blood as a marker of cartilage catabolism. , 1985, The Journal of rheumatology.

[9]  D. Heinegård,et al.  [17] Isolation and characterization of proteoglycans , 1987 .

[10]  M. Lyon,et al.  Structure and function of heparan sulphate proteoglycans. , 1986, The Biochemical journal.

[11]  G. Rodgers,et al.  Acquired heparinlike anticoagulant in a patient with metastatic breast carcinoma. , 1985, The Western journal of medicine.

[12]  I. Staprans,et al.  Isolation and characterization of glycosaminoglycans in human plasma. , 1985, The Journal of clinical investigation.

[13]  D. Danley,et al.  Heparin-like anticoagulant associated with plasma cell myeloma. , 1985, American journal of clinical pathology.

[14]  H. Gralnick,et al.  Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. , 1984, The New England journal of medicine.

[15]  Denis R. Miller,et al.  A heparin‐like anticoagulant in an 8‐month‐old boy with acute monoblastic leukemia , 1984, American journal of hematology.

[16]  R. Iozzo.  Proteoglycans and neoplastic--mesenchymal cell interactions. , 1984, Human pathology.

[17]  D. Levitt,et al.  Induction of chondroitin sulfate proteoglycan synthesis and secretion in lymphocytes and monocytes , 1983, The Journal of cell biology.

[18]  K. Mann,et al.  Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. , 1980, The Journal of clinical investigation.

[19]  F. Gyorkey,et al.  Plasma glycosaminoglycans in normal individuals of various age. , 1977, Atherosclerosis.

[20]  C. Friman,et al.  Isolation and characterization of undersulphated chondroitin-4-sulphate from normal human plasma. , 1975, Biochimica et biophysica acta.

[21]  M. Schifflers,et al.  Micromethod for the determination of glycosaminoglycans in the serum. Results from the serum of healthy and varicose subjects. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[22]  J. Kojima,et al.  The glycosaminoglycans in human hepatic cancer. , 1975, Cancer research.

[23]  Taniguchi Noboru,et al.  Isolation and preliminary characterization of glycosaminoglycans in human plasma , 1974 .

[24]  N. Blumenkrantz,et al.  New method for quantitative determination of uronic acids. , 1973, Analytical biochemistry.

[25]  E. Lüscher,et al.  Characterization of a chondroitin 4 -sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4 ) released from human blood platelets. , 1972, Biochimica et biophysica acta.

[26]  A. Veis,et al.  Microanalysis and characterization of acidic glycosaminoglycans in human tissues. , 1970, Analytical biochemistry.

[27]  N. Di Ferrante,et al.  The glycosaminoglycans of human plasma. , 1969, The Journal of clinical investigation.

[28]  M. Seraydarian,et al.  Acid mucopolysaccharides in normal serum. , 1957, The Journal of clinical investigation.

[29]  M. Schubert,et al.  Plasma polysaccharide fraction containing uronic acid, in normal subjects and in patients with rheumatoid arthritis. , 1955, The Journal of clinical investigation.

[30]  L. Hewitt.  Separation of serum albumin into two fractions: Observations on the nature of the glycoprotein fraction. , 1937, The Biochemical journal.

[31]  L. Hewitt.  Separation of serum albumin into two fractions. I. , 1936, The Biochemical journal.